腹膜透析相关腹膜炎中万古霉素血清谷浓度与临床结局的关联
该单中心回顾性队列纳入98例接受腹腔内万古霉素治疗的腹膜透析相关腹膜炎成人患者,发现81%治愈,谷浓度≥15 mg/l者治愈 odds 是<15 mg/l者的7.58倍(95%CI 1.71-33.57,P=0.008),ROC分析最佳判别阈值为14.4 mg/l。
要点
- 谷浓度≥15 mg/l与治愈率显著正相关(OR 7.58)。
- ROC分析提示最佳目标谷浓度为14.4 mg/l。
- 维持谷浓度>14–15 mg/l可能改善临床结局。
核心结论
- 腹腔内万古霉素血清谷浓度升高与腹膜透析相关腹膜炎治愈 odds 增加相关。
- 维持万古霉素血清谷浓度高于14–15 mg/l贯穿治疗全程可能改善临床结局。
研究设计与样本
- 回顾性单中心成人队列研究,纳入2016年1月至2022年5月98例接受腹腔内万古霉素治疗的腹膜透析相关腹膜炎患者。
- 采用 logistic 回归模型评估谷浓度与治愈的关联,先未调整,后调整年龄、性别、体重、GFR及腹膜透析总天数。
- 万古霉素作为连续暴露(每1 mg/l增加)和分类暴露(<15 mg/l vs. ≥15 mg/l)分别评估。
- 构建ROC曲线探索谷浓度阈值以识别治疗期间最佳目标水平。
主要发现
- 81%的患者达到治愈。
- 谷浓度≥15 mg/l的患者治愈 odds 是<15 mg/l者的7.58倍(95%CI 1.71-33.57,P=0.008)。
- 体重、GFR、腹膜透析天数、性别和年龄与结局无独立关联。
- ROC分析中判别治愈能力最强的万古霉素浓度为14.4 mg/l。
关键数值与推荐
- 分类暴露阈值:谷浓度<15 mg/l vs. ≥15 mg/l。
- 连续暴露:万古霉素谷浓度每1 mg/l增加。
- ROC分析最佳判别阈值为14.4 mg/l。
临床怎么用
- 在腹膜透析相关腹膜炎腹腔内万古霉素治疗中,可考虑监测血清谷浓度并维持高于14–15 mg/l。
- 谷浓度≥15 mg/l与更高治愈 odds 相关,可作为治疗药物监测的参考目标。
局限性
- 回顾性单中心设计,样本量98例,可能存在选择偏倚和混杂。
- 仅评估谷浓度与治愈关联,未报告其他临床结局或安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Intraperitoneal (IP) vancomycin is often first-line empiric therapy and then maintenance therapy for peritoneal dialysis (PD) peritonitis. However, how vancomycin serum levels correlate with clinical outcomes remains unclear. METHODS: We conducted a retrospective single-center adult cohort study of 98 patients with PD peritonitis treated with IP vancomycin between January 2016 and May 2022. The association between nadir vancomycin level and cure was evaluated in a logistic regression model, first unadjusted and then adjusted for age, sex, weight, glomerular filtration rate (GFR), and total number of days on PD. Vancomycin was assessed both as a continuous exposure (per 1 mg/l increase) and as a categorical exposure (<15 mg/l vs. ≥15 mg/l). A receiver operating characteristic curve (ROC) was created to explore nadir vancomycin level thresholds in an attempt to identify an optimal target level during treatment. RESULTS: Of the patients, 81% achieved cure, and patients with nadir vancomycin level ≥15 mg/l were 7.5 times more likely to experience cure compared to those with a nadir level <15 mg/l (odds ratio [OR] 7.58, 95% confidence interval [CI] 1.71-33.57, P = 0.008). Weight, GFR, days on PD, sex, and age were not independently associated with outcome. The vancomycin level with the greatest discriminatory capacity for cure on the ROC analysis was 14.4 mg/l. CONCLUSION: Increasing IP vancomycin serum levels are associated with increased odds of cure; and maintaining vancomycin serum levels above 14-15 mg/l throughout the course of PD peritonitis treatment is likely to improve clinical outcomes.
引用
- Deacon E, Canney M, McCormick B, et al. The Association Between Serum Vancomycin Level and Clinical Outcome in Patients With Peritoneal Dialysis Associated Peritonitis. Kidney Int Rep. 2023. PMID: 38106569. doi:10.1016/j.ekir.2023.09.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。